Lipids & metabolic liver disease
Management of metabolic dysfunction–associated steatotic liver disease ( MASLD )—An expert consensus statement from Indian diabetologists' perspective
Recommendations
As issued by the authors
Serum biomarkers, simple non-invasive tools and imaging techniques could direct risk stratification of patients
Early lifestyle interventions including weight loss and exercise are beneficial
The pharmacological landscape of drugs targeting insulin resistance, lipid metabolism, oxidative stress, inflammation, apoptosis and fibrogenesis pathways for MASLD is expanding
Original publication
Management of metabolic dysfunction–associated steatotic liver disease ( MASLD )—An expert consensus statement from Indian diabetologists' perspective. Diabetes Obes Metab. Published 2 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →